12:00 AM
 | 
Sep 14, 2009
 |  BioCentury  |  Emerging Company Profile

FAB Pharma: Narrower is Better

FAB Pharma S.A.S. believes that by targeting a new mechanism of action in the fatty acid biosynthesis pathway, it can develop narrow-spectrum antibiotics against methicillin-resistant Staphylococcus aureus with a much better side effect profile than existing drugs.

FAB spun out of Mutabilis S.A. in July 2009 with lead compound Fab-001. The company was to announce on Monday that it started a Phase I trial of the antibiotic to treat MRSA infections and that it raised €2.3 million ($3.3 million) in a series A round co-led by Bioam Gestion and CDC Innovation.

According to FAB CEO Stefan Fischer, who was CEO of Mutabilis, the parent company could not raise enough money to fund both the MRSA program and its earlier discovery programs,...

Read the full 597 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >